Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 24, 2015 - Issue 12
Submit an article Journal homepage
614
Views
38
CrossRef citations to date
0
Altmetric
Reviews

Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease

Karsten WickeAbbVie Deutschland GmbH & Co KG, Neuroscience Research, Department of Pharmacology, Knollstrasse, Ludwigshafen67061, GermanyCorrespondence[email protected]
,
Andreas HauptAbbVie Deutschland GmbH & Co KG, Neuroscience Research, Department of Medicinal Chemistry, Knollstrasse, Ludwigshafen67061, Germany
&
Anton BespalovAbbVie Deutschland GmbH & Co KG, Neuroscience Research, Department of Pharmacology, Knollstrasse, Ludwigshafen67061, Germany
Pages 1515-1528 | Published online: 07 Nov 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.
  • Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5:S5.
  • Kumar A, Singh A. Ekavali: a review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67:195–203.
  • Monsma FJ, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43:320–327.
  • Ward RP, Hamblin MW, Lachowicz JE, et al. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience. 1995;64:1105–1111.
  • De Jong I, Helboe L. Distribution of serotonin receptor 5-HT6 mRNA in selected neuronal populations in rat brain: a double-labelling in situ hybridization study. Alzheimers Dement. 2014;10:P925–P926.
  • Roberts JC, Hirst W, Reavill C, et al. Autoradiographic localization of the 5-HT6 receptor in the CNS of the rat using [125I]SB-258585. Br J Pharmacol. 2000;128:156P.
  • Gerard C, El Mestikawy S, Lebrand C, et al. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse. 1996;23:164–173.
  • Marcos B, Gil-Bea FJ, Hirst WD, et al. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci. 2006;24:1299–1306.
  • Hirst WD, Abrahamsen B, Blaney FE, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol. 2003;64:1295–1308.
  • Da Silva Costa V, Duchatelle P, Boulouard M, et al. Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse. Neuropsychopharmacology. 2009;34:488–500.
  • Da Silva Costa-Aze V, Dauphin F, Boulouard M. Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice. Behav Brain Res. 2011;222:134–140.
  • Riemer C, Borroni E, Levet-Trafit B, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem. 2003;46:1273–1276.
  • Dawson LA, Nguyen HQ, Li P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001;25:662–668.
  • Tassone A, Madeo G, Schirinzi T, et al. Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. Neuropharmacology. 2011;61:632–637.
  • West PJ, Marcy VR, Marino MJ, et al. Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience. 2009;164:692–701.
  • Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology. 2007;33:1323–1335.
  • Upton N, Chuang TT, Hunter AJ, et al. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics. 2008;5:458–469.
  • Lacroix LP, Dawson LA, Hagan JJ, et al. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse. 2004;51:158–164.
  • Brouard JT, Schweimer JV, Houlton R, et al. Pharmacological evidence for 5-HT6 receptor modulation of 5-HT neuron firing in vivo. ACS Chem Neurosci. 2015;6:1241–1247.
  • Minabe Y, Shirayama Y, Hashimoto K, et al. Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse. 2004;52:20–28.
  • Borsini F, Bordi F, Poggi A, et al. Effects of ST1936, a selective serotonin-6 agonist, on electrical activity of putative mesencephalic dopaminergic neurons in the rat brain. J Psychopharmacol. 2015;29:802–811.
  • Meneses A. Role of 5-HT6 receptors in memory formation. Drug News Perspect. 2001;14:396–400.
  • Meneses A. Memory formation and memory alterations: 5-HT6 and 5-HT7 receptors, novel alternative. Rev Neurosci. 2014;25:325–356.
  • Kendall I, Slotten HA, Codony X, et al. E-6801, a 5-HT(6) receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl). 2011;213:413–430.
  • Nikiforuk A, Fijal K, Potasiewicz A, et al. The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats. J Psychopharmacol. 2013;27:469–476.
  • Jastrzebska-Wiesek M, Siwek A, Kazek G, et al. Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. Pharmacol Rep. 2013;65:998–1005.
  • Borsini F, Bordi F, Riccioni T. 5-HT(6) pharmacology inconsistencies. Pharmacol Biochem Behav. 2011;98:169–172.
  • Mitchell ES, Sexton T, Neumaier JF. Increased expression of 5-HT6 receptors in the rat dorsomedial striatum impairs instrumental learning. Neuropsychopharmacology. 2007;32:1520–1530.
  • Hirst WD, Stean TO, Rogers DC, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol. 2006;553:109–119.
  • Lindner MD, Hodges DB Jr., Hogan JB, et al. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther. 2003;307:682–691.
  • Foley AG, Murphy KJ, Hirst WD, et al. The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology. 2004;29:93–100.
  • Mitchell ES, McDevitt RA, Neumaier JF. Adaptations in 5-HT receptor expression and function: implications for treatment of cognitive impairment in aging. J Neurosci Res. 2009;87:2803–2811.
  • Quiedeville A, Boulouard M, Hamidouche K, et al. Chronic activation of 5-HT4 receptors or blockade of 5-HT6 receptors improve memory performances. Behav Brain Res. 2015;293:10–17.
  • Callaghan CK, Hok V, La-Chiesa A, et al. Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457. Neuropharmacology. 2012;63:890–897.
  • Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106S–115S.
  • Arnt J, Olsen CK. 5-HT6 receptor ligands and their antipsychotic potential. Int Rev Neurobiol. 2011;96:141–161.
  • Wesolowska A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol Rep. 2010;62:564–577.
  • Wesolowska A, Nikiforuk A, Stachowicz K. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol. 2007;18:439–446.
  • Carr GV, Schechter LE, Lucki I. Antidepressant and anxiolytic effects of selective 5-HT(6) receptor agonists in rats. Psychopharmacology (Berl). 2011;213:499–507.
  • Nikiforuk A, Kos T, Wesolowska A. The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration. Psychopharmacology (Berl). 2011;217:411–418.
  • Jastrzebska-Wiesek M, Siwek A, Partyka A, et al. Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests. Neuropharmacology. 2014;85:253–262.
  • Woolley ML, Bentley JC, Sleight AJ, et al. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology. 2001;41:210–219.
  • Fisas A, Codony X, Romero G, et al. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol. 2006;148:973–983.
  • Heal DJ, Smith SL, Fisas A, et al. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther. 2008;117:207–231.
  • Heal D, Gosden J, Smith S. The 5-HT6 receptor as a target for developing novel antiobesity drugs. Int Rev Neurobiol. 2011;96:73–109.
  • Voigt JP, Fink H. Serotonin controlling feeding and satiety. Behav Brain Res. 2015;277:14–31.
  • Frassetto A, Zhang J, Lao JZ, et al. Reduced sensitivity to diet-induced obesity in mice carrying a mutant 5-HT6 receptor. Brain Res. 2008;1236:140–144.
  • Ly S, Pishdari B, Lok LL, et al. Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013;4:191–199.
  • Morairty SR, Hedley L, Flores J, et al. Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep. 2008;31:34–44.
  • Iliff JJ, Chen MJ, Plog BA, et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci. 2014;34:16180–16193.
  • Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4:147ra111.
  • Vivian JA, Wallace TL, Basile JL, et al. Cognitive-enhancing effects of a novel 5-HT6 antagonist in rodents and primates. Presented at the 12th biennial meeting of the EBPS. In: EBPS 2007, Aug 31–Sep 3, Tübingen, Germany, 2007.
  • Gee AD, Martanello L, Johnson CD, et al. Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality. Patent WO2006053785. 2006 May 26.
  • Parker CA, Gunn RN, Rabiner EA, et al. Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012;53:295–303.
  • Schmidt E, Kuwabara H, Areberg J, et al. A clinical positron emission tomography (PET) study investigating occupancy at the 5-HT6 receptor after multiple oral doses of LU AE58054 to healthy men. Alzheimers Dement. 2014;10:P925.
  • Witten L, Bang-Andersen B, Nielsen SM, et al. Characterization of [(3)H]Lu AE60157 ([(3)H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline) binding to 5-hydroxytryptamine (5-HT) receptors in vivo. Eur J Pharmacol. 2012;676:6–11.
  • Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010;13:1021–1033.
  • De Bruin NM, Prickaerts J, Van Loevezijn A, et al. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats. Neurobiol Learn Mem. 2011;96:392–402.
  • Wilkinson D, Windfeld K, Colding-Jorgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13:1092–1099.
  • Foley AG, Hirst WD, Gallagher HC, et al. The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology. 2008;54:1166–1174.

* First preclinical evidence that 5-HT6 receptor antagonists may modulate neuronal plasticity.

  • Jacobshagen M, Niquille M, Chaumont-Dubel S, et al. The serotonin 6 receptor controls neuronal migration during corticogenesis via a ligand-independent Cdk5-dependent mechanism. Development. 2014;141:3370–3377.
  • Dayer AG, Jacobshagen M, Chaumont-Dubel S, et al. 5-HT6 receptor: a new player controlling the development of neural circuits. ACS Chem Neurosci. 2015;6:951–960.
  • Riccio O, Potter G, Walzer C, et al. Excess of serotonin affects embryonic interneuron migration through activation of the serotonin receptor 6. Mol Psychiatry. 2009;14:280–290.
  • Riccio O, Jacobshagen M, Golding B, et al. Excess of serotonin affects neocortical pyramidal neuron migration. Transl Psychiatry. 2011;1:e47.
  • Rutishauser U. Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Nat Rev Neurosci. 2008;9:26–35.
  • Berezin V, Walmod PS, Filippov M, et al. Targeting of ECM molecules and their metabolizing enzymes and receptors for the treatment of CNS diseases. Prog Brain Res. 2014;214:353–388.
  • Palop J, Mucke L. Amyloid-ß-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neuronal networks. Nat Neurosci. 2010;13:812–818.
  • Routledge C, Bromidge SM, Moss SF, et al. Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist. Br J Pharmacol. 2000;130:1606–1612.
  • Stean TO, Hirst WD, Thomas DR, et al. Pharmacological profile of SB-357134: A potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist. Pharmacol Biochemistry Behav. 2002;71:645–654.
  • Wang L, Lv Y, Deng W, et al. 5-HT6 receptor recruitment of mTOR modulates seizure activity in epilepsy. Mol Neurobiol. 2015;51:1292–1299.
  • Monti JM, Jantos H, Schechter LE. The effects of systemic and local microinjection into the central nervous system of the selective serotonin 5-HT6 receptor agonist WAY-208466 on sleep and wakefulness in the rat. Behav Brain Res. 2013;249:65–74.
  • Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373–377.
  • Riccioni T, Bordi F, Minetti P, et al. ST1936 stimulates cAMP, Ca2+, ERK1/2 and Fyn kinase through a full activation of cloned human 5-HT6 receptors. Eur J Pharmacol. 2011;661:8–14.
  • Yun HM, Kim S, Kim HJ, et al. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem. 2007;282:5496–5505.
  • Kaufman AC, Salazar SV, Haas LT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol. 2015;77:953–971.
  • Duhr F, Deleris P, Raynaud F, et al. Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth. Nat Chem Biol. 2014;10:590–597.
  • Benhamu B, Martin-Fontecha M, Vazquez-Villa H, et al. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease. J Med Chem. 2014;57:7160–7181.
  • Jayarajan P, Nirogi R, Shinde A. Effect of olanzapine on scopolamine induced deficits in differential reinforcement of low rate 72s (DRL-72s) schedule in rats: involvement of the serotonergic receptors in restoring the deficits. Eur J Pharmacol. 2013;720:344–354.
  • Yadav PN, Kroeze WK, Farrell MS, et al. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther. 2011;339:99–105.
  • Citeline © TrialTrove. clinical trial database. [cited 2015 Jul 1]. Available from: https://citeline.com/products/trialtrove/.
  • Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease. Curr Alzheimer Res. 2010;7:374–385.

** This study provides first evidence of efficacy of a 5-HT6 receptor antagonist in a Phase II study.

  • Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314.
  • Gelinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am J Occup Ther. 1999;53:471–481.
  • Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011;26:536–544.

** This study provides first evidence of efficacy of a 5-HT6 receptor antagonist in a Phase II study.

  • Brisard C, Safirstein B, Booth K, et al. Safety, tolerability, and preliminary efficacy of SAM-531, a 5-HT6 antagonist, in patients with mild-to-moderate Alzheimer’s disease: results from a phase 2a study. Poster presented at ICAD; 2010 Jul 10–15; Honolulu, HI. 2010.
  • Schneider LS. Idalopirdine for Alzheimer’s disease: written in the stars. Lancet Neurol. 2014;13:1063–1065.
  • Garcia-Alloza M, Hirst WD, Chen CP, et al. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer’s disease. Neuropsychopharmacology. 2004;29:410–416.
  • Marcos B, Garcia-Alloza M, Gil-Bea FJ, et al. Involvement of an altered 5-HT6 receptor function in behavioral symptoms of Alzheimer’s disease. J Alzheimers Dis. 2008;14:43–50.
  • Andersen VL, Hansen HD, Herth MM, et al. 11C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. Bioorg Med Chem Lett. 2015;25:1053–1056.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.